Mark J. Pettenati

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Clara D. Bloomfield, David Lawrence, John C. Byrd et al. · PubMed · 1998 · 696 citations

Mixed-phenotype Acute Leukemia, Pathology, Pharmacotherapy +16

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

Krzysztof Mrózek, Guido Marcucci, Deedra Nicolet et al. · Journal of Clinical Oncology · 2012 · 405 citations · Full text

The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies

Jan O. Korbel, Tal Tirosh‐Wagner, Alexander E. Urban et al. · Proceedings of the National Academy of Sciences · 2009 · 393 citations · Full text

Down Syndrome, Severe Mental Retardation, Developmental Biology +14

Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study

Guido Marcucci, Krzysztof Mrózek, Amy S. Ruppert et al. · Journal of Clinical Oncology · 2005 · 381 citations

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461

Sherif S. Farag, Kellie J. Archer, Krzysztof Mrózek et al. · Blood · 2006 · 329 citations · Full text